Gubra ApS is a Danish biotechnology and preclinical research company based in Hørsholm. It operates as both a drug discovery organization and a contract research partner, with a primary focus on metabolic and cardiometabolic diseases such as obesity, diabetes, and nonalcoholic steatohepatitis (NASH), as well as fibrosis-related indications.
The company’s capabilities span peptide and medicinal chemistry, in vitro and in vivo pharmacology models, biomarker analysis, quantitative histology and digital pathology, imaging, and PK/PD assessment. Gubra supports partners across target validation, lead identification and optimization, and translational studies that link preclinical data to clinical endpoints. In addition to collaborative projects with pharmaceutical and biotech companies, it advances proprietary discovery programs, particularly in peptide-based therapeutics. Its work is relevant to the chemical and life sciences sectors through expertise in peptide design, synthesis, and analytical characterization.
None yet. When a new project in the record names Gubra as owner, partner or investor, it shows here.
Phase II starts for a potential first‑in‑class triple GLP‑1/GIP/NPY2 receptor agonist targeting weight, satiety and central hunger signalling; study includes dose finding and safety/efficacy evaluation.
BI 3034701 shows promise in Phase I for obesity treatment, demonstrating safety and weight loss, advancing to mid-stage development.
